Cargando...
Modulation of genomic and epigenetic end-points by celecoxib
Celecoxib, a nonsteroidal anti-inflammatory drug that selectively targets cyclooxygenase-2, is a promising cancer chemopreventive agent. However, safety concerns have been raised in clinical trials evaluating its ability to prevent colorectal adenomas. The rationale for the herein reported studies w...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154745/ https://ncbi.nlm.nih.gov/pubmed/30263093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26062 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|